Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 12, pp 2475–2484 | Cite as

Kaposiform hemangioendothelioma without cutaneous involvement

  • Yi Ji
  • Siyuan Chen
  • Lizhi Li
  • Kaiying Yang
  • Chunchao Xia
  • Li Li
  • Gang Yang
  • Feiteng Kong
  • Guoyan Lu
  • Xingtao Liu
Original Article – Clinical Oncology
  • 41 Downloads

Abstract

Purpose

We sought to characterize the clinical features and management of patients diagnosed as Kaposiform hemangioendothelioma (KHE) without cutaneous involvement.

Methods

The electronic patient chats at six Triple A hospitals in China were searched to find all patient diagnoses with KHE without cutaneous involvement.

Results

Of 30 patients (mean age at diagnosis, 55.6 months), 17 (56.7%) were male. Fourteen (46.7%) patients were associated with Kasabach–Merritt phenomenon (KMP). Patients with KMP were significantly more likely to have lesions involving truck compared to patients without KMP (odds ratio 10.000; 95% confidence interval 1.641–60.921; P = 0.011). Other common complication included severe anemia and decreased range of motion. In the majority of cases (93.3%), the lesions were highly infiltrative and locally invasive with ill-defined margins. Histological examination was required in all patients without KMP for precise diagnosis. In all, 16 (53.3%) patients received corticosteroid treatment, 19 (63.3%) received oral sirolimus treatment, 7 (23.3%) received intravenous vincristine, and 5 (16.7%) patients used propranolol. Patients had varied responses to conventional drugs, whereas all patients receiving sirolimus treatment had better response. In all, three patients (10%) died of disease, all presented with KMP. Feature of these recalcitrant cases (death) included young age, visceral location, extensive involvement, and lack of improvement with high-dose corticosteroids.

Conclusions

Our study clearly demonstrated that KHE without cutaneous involvement could be associated with important complication, which might result in death or severe morbidity. Increased awareness of KHE without cutaneous involvement is required for early diagnosis and aggressive therapy in an attempt to prevent complication.

Keywords

Kaposiform hemangioendothelioma Cutaneous involvement Kasabach–Merritt phenomenon Morbidity Mortality 

Notes

Funding

This work was supported by Grants from the National Natural Science Foundation of China (Grant nos: 81401606 and 81400862) and the Science Foundation for Excellent Youth Scholars of Sichuan University (Grant no: 2015SU04A15).

Compliance with ethical standards

Conflict of interest

Author Yi Ji declares that they have no conflict of interest. Author Siyuan Chen declares that they have no conflict of interest. Author Lizhi Li declare that they have no conflict of interest. Author Kaiying Yang declares that they have no conflict of interest. Author Chunchao Xia declares that they have no conflict of interest. Author Li Li declares that they have no conflict of interest. Author Gang Yang declares that they have no conflict of interest. Author Feiteng Kong declares that they have no conflict of interest. Author Guoyan Lu declares that they have no conflict of interest. Author Xingtao Liu declares that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study. Written informed consent for publication of this study was obtained from all patients and patient’s parents.

Supplementary material

432_2018_2759_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 23 KB)
432_2018_2759_MOESM2_ESM.docx (24 kb)
Supplementary material 2 (DOCX 23 KB)

References

  1. Adams DM, Trenor CR, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG (2016) Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 137(2):e20153257.  https://doi.org/10.1542/peds.2015-3257 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS (2010) Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 55(7):1396–1398.  https://doi.org/10.1002/pbc.22766 CrossRefPubMedGoogle Scholar
  3. Boccara O, Puzenat E, Proust S, Leblanc T, Lasne D, Hadj-Rabia S, Bodemer C (2017) The effects of sirolimus on Kasabach–Merritt phenomenon coagulopathy. Br J Dermatol.  https://doi.org/10.1111/bjd.15883 CrossRefPubMedGoogle Scholar
  4. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, Trenor CR (2013) Kaposiform hemangioendothelioma: atypical features and risks of Kasabach–Merritt phenomenon in 107 referrals. J Pediatr 162(1):142–147.  https://doi.org/10.1016/j.jpeds.2012.06.044 CrossRefPubMedGoogle Scholar
  5. Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G, Mulliken JB, Trenor CR (2014) Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr 164(2):383–388.  https://doi.org/10.1016/j.jpeds.2013.10.013 CrossRefPubMedGoogle Scholar
  6. Drolet BA, Trenor CR, Brandao LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM (2013) Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 163(1):285–291.  https://doi.org/10.1016/j.jpeds.2013.03.080 CrossRefPubMedGoogle Scholar
  7. Enjolras O, Wassef M, Mazoyer E, Frieden IJ, Rieu PN, Drouet L, Taieb A, Stalder JF, Escande JP (1997) Infants with Kasabach–Merritt syndrome do not have “true” hemangiomas. J Pediatr 130(4):631–640CrossRefGoogle Scholar
  8. Enjolras O, Mulliken JB, Wassef M, Frieden IJ, Rieu PN, Burrows PE, Salhi A, Leaute-Labreze C, Kozakewich HP (2000) Residual lesions after Kasabach–Merritt phenomenon in 41 patients. J Am Acad Dermatol 42(2 Pt 1):225–235CrossRefGoogle Scholar
  9. Fernandes VM, Fargo JH, Saini S, Guerrera MF, Marcus L, Luchtman-Jones L, Adams D, Meier ER (2015) Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder. Pediatr Blood Cancer 62(5):901–904.  https://doi.org/10.1002/pbc.25278 CrossRefPubMedGoogle Scholar
  10. Fernandez-Pineda I, Lopez-Gutierrez JC, Ramirez G, Marquez C (2010) Vincristine-ticlopidine-aspirin: an effective therapy in children with Kasabach–Merritt phenomenon associated with vascular tumors. Pediatr Hematol Oncol 27(8):641–645.  https://doi.org/10.3109/08880018.2010.508299 CrossRefPubMedGoogle Scholar
  11. Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, Bernabeu-Wittel J, Ramirez-Villar GL (2013) Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach–Merritt phenomenon. Pediatr Blood Cancer 60(9):1478–1481.  https://doi.org/10.1002/pbc.24543 CrossRefPubMedGoogle Scholar
  12. Hall GW (2001) Kasabach–Merritt syndrome: pathogenesis and management. Br J Haematol 112(4):851–862CrossRefGoogle Scholar
  13. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM (2011) Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 57(6):1018–1024.  https://doi.org/10.1002/pbc.23124 CrossRefPubMedGoogle Scholar
  14. Hu PA, Zhou ZR (2018) Clinical and imaging features of Kaposiform hemangioendothelioma. Br J Radiol 91(1086):20170798.  https://doi.org/10.1259/bjr.20170798 CrossRefPubMedGoogle Scholar
  15. Iwami D, Shimaoka S, Mochizuki I, Sakuma T (2006) Kaposiform hemangioendothelioma of the mediastinum in a 7-month-old boy: a case report. J Pediatr Surg 41(8):1486–1488.  https://doi.org/10.1016/j.jpedsurg.2006.04.013 CrossRefPubMedGoogle Scholar
  16. Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, Li Y, Wang C, Yang K, Yang G, Tang X, Xu T, Wu H (2017) Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. Int J Cancer 141(4):848–855.  https://doi.org/10.1002/ijc.30775 CrossRefPubMedGoogle Scholar
  17. Ji Y, Yang K, Peng S, Chen S, Xiang B, Xu Z, Li Y (2018) Kaposiform hemangioendothelioma: clinical features, complications and risk factors for Kasabach–Merritt phenomenon. Br J Dermatol 179(2):457–463.  https://doi.org/10.1111/bjd.16400 CrossRefPubMedGoogle Scholar
  18. Kai L, Wang Z, Yao W, Dong K, Xiao X (2014) Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol 140(3):471–476.  https://doi.org/10.1007/s00432-013-1549-3 CrossRefPubMedGoogle Scholar
  19. Kasabach H, Merritt K (1940) Capillary hemangioma with extensive purpurareport of a case. Am J Dis Child 5(59):1070–1093.  https://doi.org/10.1001/archpedi.1940.01990160135009 CrossRefGoogle Scholar
  20. Lisle JW, Bradeen HA, Kalof AN (2009) Kaposiform hemangioendothelioma in multiple spinal levels without skin changes. Clin Orthop Relat Res 467(9):2464–2471.  https://doi.org/10.1007/s11999-009-0838-2 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Liu XH, Li JY, Qu XH, Yan WL, Zhang L, Yang C, Zheng JW (2016) Treatment of kaposiform hemangioendothelioma and tufted angioma. Int J Cancer 139(7):1658–1666.  https://doi.org/10.1002/ijc.30216 CrossRefPubMedGoogle Scholar
  22. Lyons LL, North PE, Mac-Moune LF, Stoler MH, Folpe AL, Weiss SW (2004) Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 28(5):559–568CrossRefGoogle Scholar
  23. Mahajan P, Margolin J, Iacobas I (2017) Kasabach–Merritt phenomenon: classic presentation and management options. Clin Med Insights Blood Disord 10:1179545X–17699849X.  https://doi.org/10.1177/1179545X17699849 CrossRefGoogle Scholar
  24. O’Rafferty C, O’Regan GM, Irvine AD, Smith OP (2015) Recent advances in the pathobiology and management of Kasabach–Merritt phenomenon. Br J Haematol 171(1):38–51.  https://doi.org/10.1111/bjh.13557 CrossRefPubMedGoogle Scholar
  25. Rodriguez V, Lee A, Witman PM, Anderson PA (2009) Kasabach–merritt phenomenon: case series and retrospective review of the mayo clinic experience. J Pediatr Hematol Oncol 31(7):522–526.  https://doi.org/10.1097/MPH.0b013e3181a71830 CrossRefPubMedGoogle Scholar
  26. Ryan C, Price V, John P, Mahant S, Baruchel S, Brandao L, Blanchette V, Pope E, Weinstein M (2010) Kasabach–Merritt phenomenon: a single centre experience. Eur J Haematol 84(2):97–104.  https://doi.org/10.1111/j.1600-0609.2009.01370.x CrossRefPubMedGoogle Scholar
  27. Ryu YJ, Choi YH, Cheon JE, Kim WS, Kim IO, Park JE, Kim YJ (2017) Imaging findings of Kaposiform hemangioendothelioma in children. Eur J Radiol 86:198–205.  https://doi.org/10.1016/j.ejrad.2016.11.015 CrossRefPubMedGoogle Scholar
  28. San MF, Spurbeck W, Budding C, Horton J (2008) Kaposiform hemangioendothelioma: a rare cause of spontaneous hemothorax in infancy. Review of the literature. J Pediatr Surg 43(1):e37–e41.  https://doi.org/10.1016/j.jpedsurg.2007.08.068 CrossRefGoogle Scholar
  29. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE (1997) Thrombocytopenic coagulopathy (Kasabach–Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 100(6):1377–1386CrossRefGoogle Scholar
  30. Schaefer BA, Wang D, Merrow AC, Dickie BH, Adams DM (2017) Long-term outcome for kaposiform hemangioendothelioma: a report of two cases. Pediatr Blood Cancer 64(2):284–286.  https://doi.org/10.1002/pbc.26224 CrossRefPubMedGoogle Scholar
  31. Tasani M, Ancliff P, Glover M (2017) Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma. Br J Dermatol.  https://doi.org/10.1111/bjd.15640 CrossRefPubMedGoogle Scholar
  32. Tlougan BE, Lee MT, Drolet BA, Frieden IJ, Adams DM, Garzon MC (2013) Medical management of tumors associated with Kasabach–Merritt phenomenon: an expert survey. J Pediatr Hematol Oncol 35(8):618–622.  https://doi.org/10.1097/MPH.0b013e318298ae9e CrossRefPubMedGoogle Scholar
  33. Wang Z, Li K, Dong K, Xiao X, Zheng S (2015a) Successful treatment of Kasabach–Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 37(1):72–73.  https://doi.org/10.1097/MPH.0000000000000068 CrossRefPubMedGoogle Scholar
  34. Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S (2015b) Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer 62(4):577–580.  https://doi.org/10.1002/pbc.25296 CrossRefPubMedGoogle Scholar
  35. Wang C, Li Y, Xiang B, Li F, Chen S, Li L, Ji Y (2017) Successful management of pancreatic Kaposiform hemangioendothelioma with sirolimus: case report and literature review. Pancreas 46(5):e39–e41.  https://doi.org/10.1097/MPA.0000000000000801 CrossRefPubMedGoogle Scholar
  36. Zhang G, Chen H, Gao Y, Liu Y, Wang J, Liu XY (2018) Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach–Merritt phenomenon: a retrospective cohort study. Br J Dermatol.  https://doi.org/10.1111/bjd.16400 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Oncology, Department of Pediatric SurgeryWest China Hospital of Sichuan UniversityChengduChina
  2. 2.Pediatric Intensive Care Unit, Department of Critical Care MedicineWest China Hospital of Sichuan UniversityChengduChina
  3. 3.Department of Pediatric SurgeryFujian Provincial HospitalFuzhouChina
  4. 4.Department of RadiologyWest China Hospital of Sichuan UniversityChengduChina
  5. 5.Laboratory of PathologyWest China Hospital of Sichuan UniversityChengduChina
  6. 6.Department of Pediatric SurgeryChengdu Shangjin Nanfu HospitalChengduChina
  7. 7.Department of Pediatric SurgerySichuan Women and Children’s HospitalChengduChina
  8. 8.Pediatric Intensive Care UnitWest China Second University Hospital, Sichuan UniversityChengduChina
  9. 9.Department of Vascular and Interventional RadiologyChengdu Women and Children’s Central HospitalChengduChina

Personalised recommendations